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A 56-year-old man with a diagnosis of epi-
dural compression of the thoracic spinal cord 
(T6 - T8) due to Burkitt's lymphoma had sur-
gical decompression with persistent myelop-
athy.  He presented with worsened lower ex-
tremity numbness and weakness after the 
fifth cycle of systemic cytarabine and in-
trathecal methotrexate.  Examination dis-
closed a spastic ataxic paraparesis, with unre-
markable serum (including vitamin B12, 
TSH, Cu++, vitamin E, syphilis IgG) and CSF 
values.  MRI of the spinal cord showed T2 
hyperintensity of the posterolateral columns, 
characteristic of chemotherapy-induced mye-
lopathy.1 
 
Myelopathy following chemotherapy is a  
rare but devastating complication (mostly 
from methotrexate and cytarabine).1,4,5  The 
latency to onset of symptoms can be delayed, 
which include back pain and a rapidly pro-
gressive paraparesis, sensory level and blad-
der/bowel involvement.2,3,5  MRI scans show 
focal cord swelling in the posterior and lat-
eral columns.1  It is a diagnosis of exclusion 
and carries a poor prognosis.5 
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Figure 1: Axial T2 image of the thoracic spine at the T4 level showing hyperintensity at the lev-
el of the posterior columns (arrow). 
 
Figure 2: Axial T2 image of the thoracic spine at the T9 level showing hyperintensity at the lev-
el of the lateral columns (arrows). 
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